#Denmark #Copenhagen #Alzheimer's Disease #ImmunoBrain #IBC-Ab002

ImmunoBrain to Present Innovative Clinical Trial Data at AD/PD™ 2026

ImmunoBrain, a pioneering biopharmaceutical firm focused on developing advanced immunotherapies for neurodegenerative conditions, has made a significant announcement regarding the upcoming Alzheimer's and Parkinson's Diseases Conference (AD/PD™) scheduled for March 17-21, 2026, in Copenhagen, Denmark. The company is set to present the Phase 1b clinical trial data for IBC-Ab002, a novel engineered antibody aimed at blocking an inhibitory immune checkpoint pathway specifically for the treatment of Alzheimer's disease and other related disorders.

This presentation will unveil the findings from 40 patients enrolled in the trial, encompassing crucial aspects such as safety, tolerability, and biomarker effectiveness across four intravenous infusions of either IBC-Ab002 or a placebo. The key session titled, "Mechanistic Modifiers of Alzheimer's Disease - APOE, Immunity, and Neural Circuits," will be presented by Professor Catherine J. Mummery, an esteemed expert in the field.

Presentation Details:

• - Session Name: Mechanistic Modifiers of AD APOE, Immunity, and Neural Circuits
• - Title: PD-L1 Immune Checkpoint Blockade in Early Alzheimer's Disease Topline Results from the Phase 1b IBC-01-01 Study (ID 2979)
• - Date and Time: Thursday, March 19, 2026, at 8:55 a.m. CET
• - Location: Hall 180-181

About IBC-Ab002 and Its Significance

IBC-Ab002 is particularly noteworthy as it represents ImmunoBrain’s ambitious approach to activating the peripheral immune system, which is deemed essential for brain protection and repair. With over 25 years of foundational research led by Professor Michal Schwartz and her team from the Weizmann Institute of Science, IBC-Ab002 offers a fresh perspective on how treatments for Alzheimer's disease could potentially harness the body's immune response to combat neurodegeneration.

The drug is a proprietary Fc-modified anti-PD-L1 monoclonal antibody that proposes a similar mechanism as checkpoint inhibitors used in cancer treatments, but is uniquely tailored for chronic neurodegenerative diseases. This aim is to provide intermittent dosing for better patient outcomes.

Furthermore, the Phase 1b trial, which is being supported by grants from the National Institute on Aging (NIA) and the Alzheimer’s Association, has recently concluded and this upcoming conference marks a pivotal moment for ImmunoBrain to share preliminary but important data that may influence future therapeutic practices.

Conclusion

ImmunoBrain’s participation at AD/PD™ 2026 underscores its commitment to pioneering novel solutions tackling complex neurodegenerative diseases, such as Alzheimer's. As the field of Alzheimer's research rapidly evolves, the insights shared during this conference will be instrumental in paving the way for future innovations in treatment approaches.

For those interested in the latest advancements in Alzheimer's therapy, ImmunoBrain's presentation promises to deliver data that may hold the key to unlocking new pathways for neurorecovery and enhancing the quality of life for millions affected by Alzheimer's disease.